Our lead substance ISR048 stimulates two of the three pathways leading to T-cell activation, which can be further amplified and extended by adding pharmaceuticals inhibiting CTLA-4 and PD-1 (i.e. Checkpoint Blockage), the subjects of this year's Nobel Prize. A phase II clinical trial with ISR048 now goes on at Karolinska University Hospital Huddinge and Södersjukhuset, with the purpose of activating the immune system to eliminate the HIV infected cells.
The recently founded subsidiary ISR Oncology AB patent protected the combination ISR050 with the addition of check point blockage for treatment of cancer, since we demonstrated a clear improvement with this combination therapy in animal studies. The company now presents the drug candidate ISR050 to an IND (Investigational New Drug), applying for a clinical trial on patients with disseminated cancer disease.
"The discoveries by Dr Allison and Dr Honjo are ground breaking for our understanding of the T-cell activation and regulation, findings which now have lead to the development of new treatment principles. For ISR this is a confirmation that we're working in the very field, which this year is rewarded by the Nobel Prize. Tremendously stimulating!", comments Ola Winqvist, CEO ISR.
For further information, please contact:
Ola Winqvist
CEO, ISR Immune System Regulation Holding AB (publ)
E-post: ola.winqvist@israb.se
Phone: +46 (0)70 5427939
About ISR Immune System Regulation Holding AB (publ)
ISR is an innovation driven pharmaceutical development company within immunotherapy. The company focuses on clinical and preclinical research, with the goal to develop a broad-spectrum antiviral platform of immune regulating pharmaceutics. Erik Penser Bank is the company's Certified Adviser, and can be reached on phone +46 (0)8-463 80 00.
www.israb.se